Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention: Erratum
In the April 15, 2024 issue of JAIDS Journal of Autoimmune Deficiency Syndromes, in the article by Erenrich et al1, “Effectiveness of PrEPTECH: Findings from a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention” mathematical errors have been published in Table 1. The percentage for Miami-Dade County has been corrected to 9.5% in the Region/Intervention cell and the percentage for San Francisco Bay has been corrected to 29.3% in the Region/Intervention cell. The published Table 1 also omits percentages from “prefer not to answer” responses. The data is not incorrect without these responses but the revised Table 1 below includes “prefer not to answer” responses for clarity.
TABLE 1. -
Baseline Sociodemographic and Behavioral Characteristics Among Study Participants (Full Sample)
Characteristics
All Participants (%, n = 229)
Intervention (%, n = 116)
Control (%, n = 113)
P
Age (yr), mean ± SD
23.7 ± 2.8
23.6 ± 2.8
23.8 ± 2.8
0.427
Highest level of schooling completed
0.004
Less than high school
9 (3.9%)
5 (4.3%)
4 (3.5%)
Graduated high school/GED
25 (10.9%)
14 (12.1%)
11 (9.7%)
Some college/technical school
108 (47.2%)
65 (56.0%)
43 (38.1%)
Bachelor's degree
71 (31.0%)
28 (24.1%)
43 (38.1%)
Graduate degree
11 (4.8%)
1 (0.9%)
10 (8.8%)
Prefer not to answer
5 (2.2%)
3 (2.6%)
2 (1.8%)
Gender identity
0.484
Cisgender male
209 (91.3%)
104 (89.7%)
105 (92.9%)
Transgender female
20 (8.7%)
12 (10.3%)
8 (7.1%)
Sexual orientation
0.766
Gay (or gay/queer)
159 (69.4%)
79 (68.1%)
80 (70.8%)
Bisexual (or bisexual/queer)
44 (19.2%)
24 (20.7%)
20 (17.7%)
Other
24 (10.5%)
11 (9.5%)
13 (11.5%)
Prefer not to answer
2 (0.9%)
2 (1.7%)
0 (0.0%)
Region
0.373
Broward county
15 (6.6%)
7 (6.0%)
8 (7.1%)
Miami-Dade county
29 (12.7%)
11 (9.5%)
18 (15.9%)
San Francisco Bay area
59 (25.8%)
34 (29.3%)
25 (22.1%)
Los Angeles county
126 (55%)
64 (55.2%)
62 (54.9%)
Race/ethnicity
0.886
White
52 (22.7%)
25 (21.6%)
27 (23.9%)
Black/African American
15 (6.6%)
9 (7.8%)
6 (5.3%)
Hispanic/Latinx
85 (37.1%)
43 (37.1%)
42 (37.2%)
Middle Eastern/North African
3 (1.3%)
1 (0.9%)
2 (1.8%)
Asian/Pacific Islander
29 (12.7%)
16 (13.8%)
13 (11.5%)
Multiracial
43 (18.8%)
21 (18.1%)
22 (19.5%)
American Indian/Alaska Native
1 (0.4%)
0 (0.0%)
1 (0.9%)
Prefer not to answer
1 (0.4%)
1 (0.9%)
0 (0.0%)
Language other than English spoken at home:
131 (57.2%)
68 (58.6%)
63 (55.8%)
0.690
Health insurance status
0.340
Public insurance
54 (23.6%)
27 (23.3%)
27 (23.9%)
Private insurance through parent
53 (23.1%)
23 (19.8%)
30 (26.5%)
Other private insurance (through school, work, affordable care Act marketplace)
63 (27.5%)
29 (25.0%)
34 (30.1%)
Uninsured
27 (11.8%)
14 (12.1%)
13 (11.5%)
Other status
20 (8.7%)
14 (12.1%)
6 (5.3%)
Prefer not to answer
12 (5.2%)
9 (7.8%)
3 (2.7%)
Lives with parent or guardian
95 (41.5%)
50 (43.1%)
45 (39.8%)
0.420
Previously took PrEP
50 (21.8%)
24 (20.7%)
26 (23.0%)
0.750
No. of sex partners, lifetime, mean ± SD
42 ± 107
54 ± 146
31 ± 39
0.121
Diagnosed with an STI, past 6 mo
198 (86.5%)
99 (85.3%)
99 (87.6%)
0.701
1. Erenrich RK, Braun RA, Torres-Mendoza DM, et al. Effectiveness of PrEPTECH: findings from a 180-day randomized controlled trial of a pre-exposure prophylaxis telehealth intervention. J Acquir Immune Defic Syndr. 2024;95:463–469.
Comments (0)